Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Income towards Parent Company: 2012-2024

Historic Income towards Parent Company for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -$5.1 million.

  • Sunshine Biopharma's Income towards Parent Company rose 26.21% to -$883,820 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 41.81%. This contributed to the annual value of -$5.1 million for FY2024, which is 13.94% down from last year.
  • According to the latest figures from FY2024, Sunshine Biopharma's Income towards Parent Company is -$5.1 million, which was down 13.94% from -$4.5 million recorded in FY2023.
  • Sunshine Biopharma's 5-year Income towards Parent Company high stood at -$2.8 million for FY2020, and its period low was -$26.7 million during FY2022.
  • For the 3-year period, Sunshine Biopharma's Income towards Parent Company averaged around -$12.1 million, with its median value being -$5.1 million (2024).
  • As far as peak fluctuations go, Sunshine Biopharma's Income towards Parent Company crashed by 378.17% in 2020, and later soared by 83.15% in 2023.
  • Sunshine Biopharma's Income towards Parent Company (Yearly) stood at -$2.8 million in 2020, then tumbled by 346.70% to -$12.4 million in 2021, then slumped by 115.05% to -$26.7 million in 2022, then skyrocketed by 83.15% to -$4.5 million in 2023, then decreased by 13.94% to -$5.1 million in 2024.